UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000058849 |
|---|---|
| Receipt number | R000067293 |
| Scientific Title | Evaluation research on the improvement of the intestinal environment in healthy adults by ingestion of test foods |
| Date of disclosure of the study information | 2025/08/20 |
| Last modified on | 2025/08/20 12:48:27 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Evaluation research on the improvement of the intestinal environment in healthy adults by ingestion of test foods
Acronym
Evaluation research on the improvement of the intestinal environment in healthy adults by ingestion of test foods
Scientific Title
Evaluation research on the improvement of the intestinal environment in healthy adults by ingestion of test foods
Scientific Title:Acronym
Evaluation research on the improvement of the intestinal environment in healthy adults by ingestion of test foods
Region
| Japan |
Condition
Condition
Healthy Adults
Classification by specialty
| Not applicable |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Examine whether foods containing kestose and agarooligosaccharides (intestinal active powdered drinks) are actually effective in improving the intestinal environment and QOL (emotions and stress), including immunity, in healthy adult men and women, and to examine the safety of using them in combination.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Fecal bacterial flora
Key secondary outcomes
Questionnaire
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Intake test food (9 g) dissolved in water or lukewarm water (100 ml) once a day for 4 weeks.
Interventions/Control_2
Intake placebo (9 g) dissolved in water or lukewarm water (100 ml) once a day for 4 weeks.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 65 | years-old | <= |
Age-upper limit
| 100 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1. Persons who are aged 65 to 100 at the time of consent, both men and women
2. Persons who are not suffering from a disease directly related to the study (including those who are judged not to need to start new treatment immediately)
3. Persons who received a sufficient explanation of the purpose and contents of the research, have the capacity to consent by themselves or legal representative
Key exclusion criteria
1. Persons who may experience abdominal pain when eating ingredients containing kestose and agarooligosaccharides
2. Persons who have been diagnosed with a digestive disease (diseases involving digestive inflammation, such as inflammatory bowel disease) and those who will require digestive surgery in the future.
3. Persons who regularly use (at least 3 days a week) kestose and agarooligosaccharides or have regularly used within the 3 months prior to the pre-test
4. Persons who have been diagnosed with malignant tumors, currently receiving treatment for cranial nerve, heart, kidney, diabetes, or thyroid dysfunction, and with a history of serious illnesses such as liver disease, excluding illnesses like hypertension, which implementing physician in charge determined will not affect the evaluation of the research.
5. Persons who drink a large amount of alcohol (60 g or more of alcohol per day: approximately 1500 mL of beer, 540 mL of wine, 3 cups of sake, or 180 mL of double-sized whiskey)
6. Persons who are at risk of developing allergies related to the test foods
7. Persons who are judged unsuitable as research subjects based on their responses to a background survey
8. Persons who have participated in other research during one month prior to the start of this research, or plan to participate in other research after consenting to this research.
9. Persons who are judged to be ineligible by the principal investigator
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | Junichi |
| Middle name | |
| Last name | Kabeya |
Organization
Nambu Co., Ltd.
Division name
Managing Director
Zip code
444-0840
Address
10-91 Ushikorobi, Tosaki-cho, Okazaki, Aichi, Japan
TEL
0564-64-0200
kabeya@nambu-y.jp
Public contact
Name of contact person
| 1st name | Takumi |
| Middle name | |
| Last name | Tochio |
Organization
Fujita Health University
Division name
Department of Gastroenterology and Hepatology
Zip code
470-1101
Address
1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, JAPAN
TEL
090-6904-6772
Homepage URL
takumitochiobiz@gmail.com
Sponsor or person
Institute
Nambu Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Nambu Co., Ltd.
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Educational Association Fujita Gakuen Fujita Health University
Name of secondary funder(s)
Ina Food Industry Co., Ltd.
WELLNEO SUGAR Co., Ltd.
IRB Contact (For public release)
Organization
The Ethics Committee
Address
1-18-26-204 Miharadai, Nerima-ku, Tokyo
Tel
080-7385-7987
info@okutoeru.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2025 | Year | 08 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2025 | Year | 02 | Month | 01 | Day |
Date of IRB
| 2025 | Year | 02 | Month | 01 | Day |
Anticipated trial start date
| 2025 | Year | 02 | Month | 02 | Day |
Last follow-up date
| 2025 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2025 | Year | 08 | Month | 20 | Day |
Last modified on
| 2025 | Year | 08 | Month | 20 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067293
